Publication record

H-index 27

Journal publications – 92

My Google Scholar page

Publications

             
HIGH-IMPACT STUDENTS’ COCHRANE REVIEWS META-ANALYSES PODCASTS PATIENT EXPERIENCES ALL

 

 

ALL JOURNAL PUBLICATIONS

Navarese EP, Gurbel PA, Andreotti F, Kolodziejczak MM, Palmer SC, Dias S, Buffon A, Kubica J, Kowalewski M, Jadczyk T, Laskiewicz M, Jedrzejek M, Brockmeyer M, Strippoli GFM. Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures: a systematic review and network meta-analysis. PLoS One. 2017;12(2): e0168726. doi: 10.1371/journal.pone.0168726. Impact factor 3.234.

Saglimbene V, Palmer SC, Craig JC, et al. Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anaemia: A randomized clinical trial. PLoS One. 2017; 12(3):e0172735. Impact factor 3.234.

Huria T, Palmer SC, Beckert L, Lacey C, Pitama S. Indigenous health: Designing a clinical orientation program valued by learners. BMC Medical Education 2017. Accepted for publication. Impact factor 1.312.

Hill P, Cross NB, Barnett ANR, Palmer SC, Webster AC. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database of Systematic Reviews 2017:CD004759. Impact factor 6.103. Citations: 0.

Palmer SC, Tunnicliffe DJ, Singh-Grewal D, Mavridis D, Tonelli M, Johnson DW, Craig JC, Tong A, Strippoli GFM. Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: A network meta-analysis of randomized trials. American Journal of Kidney Diseases 2017 Feb 20. pii: S0272-6386(17)30036-7. doi: 10.1053/j.ajkd.2016.12.008. Impact factor 6.269.

Palmer SC, Maggo JK, Campbell KL, Craig JC, Johnson DW, Sutanto B, Ruospo M, Tong A, Strippoli GFM. Dietary patterns for adults with chronic kidney disease. Cochrane Database of Systematic Reviews 2017. Accepted for publication. Impact factor 6.103. Citations: 0.

Walker RC, Walker S, Morton RL, Tong A, Howard K, Palmer SC. Māori patients’ experience and perspectives of chronic kidney disease: A New Zealand qualitative interview study. BMJ Open 2017;7(1):e013829. Impact factor 2.562.

Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. Journal of the American Medical Association 2016 July 19;316(3):313-324. Impact factor: 37.6. Citations: 18.

Puckett J, Pickering JW, Palmer SC, McCall JL, Kluger MT, De Zoysa J, Endre ZH, Soop M. Low versus standard urine output targets in patients undergoing major abdominal surgery: A randomized noninferiority trial. Annals of Surgery. 2017;265(5):874-881. Impact factor 8.569.

Badve SV, Palmer SC, Hawley CM, Pascoe EM, Strippoli GF, Johnson DW. Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials. Nephrology Dialysis Transplantation. 2016;31(9):1425-36. Impact factor 4.085. Citations: 0.

Kelly J, Palmer SC, Wai SN, Ruospo M, Carrero J-J, Campbell KL, Strippoli GFM. Healthy dietary patterns, mortality, and end-stage kidney disease in CKD: A meta-analysis of cohort studies. Clinical Journal of the American Society of Nephrology. 2016; published ahead of print December 8, 2016, doi: 10.2215/CJN.06190616. Impact factor 4.7.

Palmer SC, Gardner S, Tonelli M, Mavridis D, Johnson DW, Craig JC, French R, Ruospo M, Strippoli GF. Phosphate binding agents in adults with CKD: A network meta-analysis of randomized trials. American Journal of Kidney Diseases 2016 Jul 22. doi: 10.1053/j.ajkd.2016.05.015. Impact factor 6.269. Citations: 1.

Badve SV, Palmer SC, Strippoli GFM, Roberts MA, Teixeira-Pinto A, Boudville N, Cass A, Hawley CM, Hiremath SS, Pascoe EM, Perkovic V, Whalley GA, Craig JC, David W Johnson. The validity of left ventricular mass as a surrogate end point for all-cause and cardiovascular mortality outcomes in people with CKD: A systematic review and meta-analysis. American Journal of Kidney Diseases 2016;68(4):554-63. Impact factor 6.269. Citations: 0.

Saglimbene V, Palmer S, Scardapane M, et al. Depression and all-cause mortality in patients on haemodialysis: a multinational cohort study. Nephrology Dialysis Transplantation 2017;32(2):377-384. Impact factor: 4.085. Citations: 0.

Walker RC, Howard K, Tong A, Palmer SC, Marshall MR, Morton RL. The economic considerations of patients and caregivers in choice of dialysis modality. Hemodialysis International 2016;20(4):634-642. Impact factor: 1.240. Citations: 1.

O’Lone E, Connors M, Masson P, Wu S, Kelly PJ, Gillespie D, Parker P, Whiteley W, Strippoli G, Palmer S, Craig JC, Webster AC. Cognition in people with end-stage kidney disease treated with hemodialysis: a systematic review and meta-analysis.  American Journal of Kidney Diseases 2016;67(6):925-935. Impact factor 6.269. Citations: 0.

Palmer SC, Natale P, Ruospo M, Saglimbene VM, Rabindranath KS, Craig JC, Strippoli GFM. Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD004541. DOI: 10.1002/14651858.cd004541.pub3. Impact factor 6.103. Citations: 0.

Ravani P, Quinn RR, Oliver MJ, Karsanji DJ, James MT, MacRae JM, Palmer SC, Strippoli GFM. Pre-emptive correction of arteriovenous access stenosis: systematic review and meta-analysis of randomized controlled trials. American Journal of Kidney Diseases 2016;67(3):446-60. Impact factor 6.269. Citations: 2.

Palmer SC, Ruospo M, Wong G, et al. Patterns of oral disease in adults with chronic kidney disease treated with hemodialysis. Nephrology Dialysis Transplantation 2016;31(10):1647-53. Impact factor: 4.085. Citations: 1.

Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheeler DC, Strippoli GFM. Comparative efficacy and safety of blood pressure lowering agents in adults with diabetes and kidney disease: A network meta-analysis. The Lancet 2015; 385(9982):2047-2056 [with editorial]. Impact factor: 45.2. Citations: 57.

Palmer SC, Teixeira-Pinto A, Saglimbene V, Craig JC, Macaskill P, Tonelli M, de Berardis G, Ruospo M, Strippoli GF. Association of drug effects on serum parathyroid hormone, phosphorus, and calcium levels with mortality in CKD: A meta-analysis. American Journal of Kidney Diseases 2015; 66(6):962-971. Impact factor 6.269. Citations: 8.

Kaminski MR, Raspovic A, McMahon LP, Strippoli SC, Ruospo M, Dallimore S, Mandorf KB. Risk factors for foot ulceration and lower extremity amputation in adults with end-stage renal disease on dialysis: A systematic review and meta-analysis. Nephrology Dialysis Transplantation 2015;30(10):1747-1766. Impact factor 4.085. Citations: 4.

Palmer SC, Ruospo M, Wong G, Craig JC, Petruzzi M, De Benedittis M, Ford P, Johnson DW, Tonelli M, Natale P, Saglimbene V, Pellegrini F, Celia E, Gelfman R, Leal MR, Torok M, Stroumza P, Bednarek-Skublewska A, Dulawa J, Frantzen L, Ferrari JN, Del Castillo D, Bernat AG, Hegbrant J, Wollheim C, Gargano L, Bots CP, Strippoli G; ORAL-D Investigators. Dental health and mortality in people with end-stage kidney disease treated with hemodialysis: A multinational cohort study. American Journal of Kidney Diseases 2015;66(4):666-676. Impact factor 6.269. Citations: 5.

Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GF. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database of Systematic Reviews 2015;7:CD010294. Impact factor 6.103. Citations: 5.

Lo P, Sharma A, Craig JC, Wyburn K, Lim W, Palmer SC, Strippoli GF, Wong G. Preconditioning therapy in ABO-incompatible living kidney transplantation: A systematic review and meta-analysis. Transplantation 100(4):933-42. Impact factor 3.690. Citations: 0.

Vecchio M, Bonarba B, Palmer SC, Craig JC, Ruospo M, Samuels JA, Molony DA, Schena FP, Strippoli GF. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database of Systematic Reviews 2015;8:CD003965. Impact factor 6.103. Citations: 0.

Walker RC, Howard K, Morton RL, Palmer SC, Marshall MR, Tong A. Patient and caregiver values, beliefs and experiences when considering home dialysis as a treatment option: a semi-structured interview study. Nephrology Dialysis Transplantation 2016;31(1):133-141. Impact factor 4.085. Citations: 2.

Walker RC, Morton RL, Tong A, Marshall MR, Palmer S, Howard K. Patient and caregiver preferences for home dialysis – The Home First Study: A protocol for qualitative interviews and discrete choice experiments. BMJ Open 2015;5(4):e007405. Impact factor 2.271. Citations: 13.

Palmer SC, Ruospo M, Campbell KL, et al. Nutrition and dietary intake and their association with mortality and hospitalization in adults with chronic kidney disease treated with haemodialysis: Protocol for DIET-HD, a prospective, multinational, cohort study. BMJ Open 2015;5:e006897 doi:10.1136/bmjopen-2014-006897. Impact factor 2.271. Citations: 0.

Ballinger AE, Palmer SC, Nistor I, Craig JC, Strippoli GF. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database of Systematic Reviews 2014 Dec 9;12. doi: 10.1002/14651858.CD006254.pub2. Epub 2014 Dec 9. Impact factor 5.77. Citations: 11.

Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database of Systematic Reviews 2014 Dec 8;12:CD010590. doi: 10.1002/14651858.CD010590.pub2. Impact factor 5.77. Citations: 20.

Palmer SC, Palmer AR, Craig JC, Johnson DW, Stroumza P, Frantzen L, Leal M, Hoischen S, Hegbrant J, Strippoli GF. Home versus in-centre haemodialysis for end-stage kidney disease. Cochrane Database of Systematic Reviews 2014 Nov 20;11:CD009535. doi: 10.1002/14651858.CD009535.pub2. Impact factor 5.77. Citations: 2.

Tong A, Rangan GK, Ruospo M, Saglimbene V, Strippoli GFM, Palmer S, Tunnicliffe D, Craig JC. A painful inheritance – patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research. Nephrology Dialysis Transplantation 2015;30(5):790-800. Impact factor 3.564. Citations: 7.

Walker R, Hanson CS, Palmer SC, Howard K, Morton RL, Marshall MR, Tong A. Patient and caregiver perspectives on home hemodialysis: A systematic review. American Journal of Kidney Diseases 2015;65(3):451-463. Impact factor: 5.15. Citations: 15.

Palmer SC, Hanson CS, Craig JC, Strippoli GFM, Ruospo M, Campbell K, Johnson DW, Tong A. Dietary and fluid restrictions in CKD: A thematic synthesis of patient views from qualitative studies. American Journal of Kidney Diseases 2015;65(4):559-573. Impact factor: 5.15. Citations: 4.

Pickering JW, James MT, Palmer SC. Acute kidney injury and prognosis after cardiopulmonary bypass: a meta-analysis of cohort studies. American Journal of Kidney Diseases 2015;65(2):283-293. Impact factor: 5.15 Citations: 34.

Casey JR, Hanson CS, Winkelmayer WC, Craig JC, Palmer S, Strippoli GFM, Tong A. Anything but a simple surgical procedure: a systematic review of patients’ perspectives on vascular access for hemodialysis. American Journal of Kidney Diseases 2014; 64(6):937-53. Impact factor: 5.15 Citations: 0.

Kabani R, Quinn RR, Palmer S, Lewin AM, Yilmaz S, Tibbles LA, Lorenzetti DL, Strippoli GFM, McLaughlin K, Ravani P. Risk of death following kidney allograft failure: a systematic review and meta-analysis of cohort studies. Nephrology Dialysis Transplantation 2014; 29(9):1778-86. Impact factor 3.564. Citations: 3.

Bolignano D, Palmer SC, Navaneethan SD, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD007004. DOI: 10.1002/14651858.CD007004.pub3. Impact factor 5.77. Citations: 28.

Palmer SC, de Berardis G, Craig JC, Tong A, Tonelli M, Pellegrini F, Ruospo M, Hegbrant J, Wollheim C, Celia E, Gelfman R, Ferrari JN, Torok M, Murgo M, Leal M, Bednarek-Skublewska A, Dulawa J, Strippoli G. Patient satisfaction with in-centre haemodialysis care: an international survey. BMJ Open 2014 DOI: 10.1136/bmjopen-2014-005020. Impact factor: 1.58. Citations: 6.

Ballinger AE, Palmer SC, Wiggins KJ, Craig JC, Cross NB, Strippoli GFM. Treatment for peritoneal dialysis associated peritonitis. Cochrane Database of Systematic Reviews 2014, Issue 4. Art No.: CD005284. DOI: 10.1002/14651858.CD005284.pub3. Impact factor 5.77. Citations: 13.

Palmer SC, Saglimbene V, Craig JC, Navaneethan SD, Strippoli GFM. Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database of Systematic Reviews 2014 Issue 3 Art No.: CD009297. DOI: 10.1002/1461858.CD009297.pub2. Impact factor 5.77. Citations: 2.

Palmer BR, Slow S, Ellis KL, Pilbrow A, Skelton L, Frampton CM, Palmer SC, Troughton RW, Yandle TG, Doughty RN, Whalley GA, Leveer M, George PM, Cameron VA. Genetic polymorphism rs6922269 in the MTHFD1L gene is associated with survival and baseline active vitamin B12 levels on post-acute coronary syndromes patients. PLoS One 2014. DOI: 10.1371/journal.pone.0089029. Impact factor: 3.73. Citations: 2.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews 2014 May 31;(50:CD007784. DOI: 10.1002/14651858. Impact factor: 6.51. Citations: 46.

Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegrant J, Strippoli GFM. HMG CoA reductase inhibitors (statins) for kidney transplant recipients (Review). Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD005019. DOI: 10.1002/14651858.CD005019.pub4. Impact factor: 6.51. Citations: 13.

Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews 2014 Jan 28;1:CD005019. Impact factor: 6.51. Citations: 15.

Nistor I,* Palmer SC,* Craig JC, Saglimbene V, Vecchio M, Covic A, Strippoli GFM. Convective versus diffusive therapies for chronic kidney failure: An updated systematic review of randomized trials. American Journal of Kidney Diseases 2014; 63(6):954-967. Impact factor: 5.15 *Equal first authorship. Citations: 31.

Palmer S, Wong G, Iff S, Yang J, Jayaswal V, Craig JC, Rochtchina E, Mitchell P, Wang J J, Strippoli GFM. Fluid intake and all-cause mortality, cardiovascular mortality, and kidney function: A population-based cohort study. Nephrology Dialysis Transplantation 2014;29(7):1377-84. Impact factor 3.564. Citations: 12.

Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoysa JR, Fassett RG, Faull R, Harris DC, Hawley CM, Kanellis J, Palmer SC, Perkovic V, Pascoe EM, Rangan GK, Walker RJ, Walters G, Johnson DW. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrology Dialysis Transplantation 2014;29(2):406-13. Impact factor 3.564. Citations: 46.

Ruospo M, Palmer S, Craig JC, Gentile G, Johnson DW, Ford P, Tonelli M, Petruzzi M, De Benedictis M, Strippoli GFM. Prevalence and severity of oral disease in adults with chronic kidney disease: A systematic review of observational studies. Nephrology Dialysis Transplantation 2014; 29(2):364-75. Impact factor 3.564. Citations: 21.

Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, Covic A, Strippoli GFM. Calcimimetic agents in people with chronic kidney disease: A cumulative meta-analysis of randomized controlled trials. PLoS Medicine 2013;10(4):e1001436 Impact factor: 16.27. Citations: 40.

Ravani P, Palmer SC, Oliver MJ, Quinn RR, MacRae JM, Tai DJ, Pannu NI, Thomas C, Hemmelgarn BR, Craig JC, Manns B, Tonelli M, Strippoli GFM, James MT. Association between hemodialysis vascular access type and clinical outcomes: Meta-analysis of cohort studies. Journal of the American Society of Nephrology 2013;24(3):465-73 Impact factor: 9.663. Citations: 114.

Strippoli GFM, Palmer SC, Ruospo M, Saglimbene V, Craig JC, Pellegrini F, Petruzzi M, De Benedittis M, Ford P, Johnson DW, Frantzen L, Torok M, Leal MR, Celia E, Gelfman R, Bednarek-Skublewska A, Dulawa J, Nin Ferrari J, Del Castillo D, Hegbrant J, Wollheim C. Oral disease in adults treated with hemodialysis: Prevalence, predictors, and association with mortality and adverse cardiovascular events: The rationale and design of the ORAL Diseases in hemodialysis (ORAL-D) study, a prospective, multinational, longitudinal, observational, cohort study. BMC Nephrology 2013;14:90. Impact factor: 2.18. Citations: 10.

Lewis L, Raudsepp SD, Yandle TG, Frampton CM, Palmer SC, Troughton RW, Richards AM. Comparison of immunoassays for NTproBNP conducted on three analysis systems: Milliplex, Elecsys, and RIA. Clinical Biochemistry 2013;46(4-5):388-90. Impact factor: 2.36. Citations: 3.

Ralib AM, Pickering JW, Major T, Palmer SC, Shaw GM, Goodkin DA, Endre ZH. High-dose intravenous epoetin does not increase blood pressure in critically ill patients with acute kidney injury. Clinical Nephrology 2013;79(5): 370-379. Impact factor: 1.19. Citations: 1.

Greenslade JH, Cullen L, Kalinowski L, Parsonage W, Palmer S, Aldous S, Richards M, Troughton R, Pemberton C, Than M. Examining renal impairment as a risk factor for acute coronary syndrome: A prospective observational study. Annals of Emergency Medicine.  2013; 62(1):38-46. Impact factor: 4.43. Citations: 3.

Palmer SC, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, Pellegrini F, Saglimbene V, Logroscino G, Fishbane S, Strippoli GFM. Prevalence of depression in chronic kidney disease: Systematic review and meta-analysis of observational studies. Kidney International 2013; 84(1):179-91. Impact factor: 6.06. Citations: 91.

Palmer SC, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, Pellegrini F, Saglimbene V, Logroscino G, Hedayati SS, Strippoli GFM. Association between depression and death in people with CKD: A meta-analysis of cohort studies. American Journal of Kidney Diseases 2013; 62(3):493-505. Impact factor: 5.15. Citations: 32.

Tong A, Palmer S, Manns B, Craig JC, Ruospo M, Gargano L, Johnson DJ, Hegbrant J, Olsson M, Fishbane S, Strippoli GFM. The beliefs and expectations of patients and caregivers about home haemodialysis: An interview study BMJ Open 2013;3:e002148 doi:10.1136/bmjopen-2012-002148. Impact factor: 1.58. Citations: 15.

Tong A, Palmer S, Manns B, Craig JC, Ruospo M, Gargano L, Johnson DW, Hegbrant J, Olsson M, Strippoli GFM. Clinician beliefs and attitudes about home haemodialysis: A multinational interview study. BMJ Open 2012;2: e002146 doi:10.1136/bmjopen-2012-002146. Impact factor: 1.58. Citations: 8.

Palmer SC, Di Micco L, Razavian M, Craig JC, Ravani P, Perkovic V, Tognoni G, Graziano G, Jardine M, Pellegrini F, Nicolucci A, Webster A, Strippoli GFM. Antiplatelet therapy to prevent hemodialysis vascular access failure: Systematic review and meta-analysis. American Journal of Kidney Diseases 2013;61(1):112-122. Impact factor: 5.15. Citations: 24.

Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GFM. Benefits and harms of statin therapy for persons with chronic kidney disease. A systematic review and meta-analysis. Annals of Internal Medicine 2012; 157(4):263-75 Impact factor: 16.7 Citations: 154.

Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Tognoni G, Graziano G, Pellegrini F, Jardine M, Webster A, Nicolucci A, Zoungas S, Strippoli GFM. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease. Annals of Internal Medicine 2012;156(6):445-59 Impact factor: 16.7 Citations: 68.

Palmer SC, Rabindranath KS, Craig JC, Roderick PJ, Locatelli F, Strippoli GFM. High-flux versus low-flux membranes for end-stage kidney disease. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD005016. DOI: 10.1002/14651858.CD005016.pub2. Impact factor: 6.186. Citations: 4.

Collaborative Depression and Sexual Dysfunction (CDS) in Hemodialysis Working Group. Sexual dysfunction in women with end-stage kidney disease requiring hemodialysis. Clinical Journal of the American Society of Nephrology 2012; 7(6):974-981. Impact factor: 4.763. Citations: 7.

Pemberton CJ, Siriwardena M, Kleffman T, Ruygrok P, Palmer SC, Yandle TG, Richards M. First identification of circulating prepro-A-type natriuretic peptide (PreproANP) signal peptide fragments in humans: Initial assessment as cardiovascular biomarkers. Clinical Chemistry 2012; 58(4):757-767. Impact factor:  6.886. Citations: 10.

Collaborative Depression and Sexual Dysfunction (CDS) in Hemodialysis Working Group. Prevalence and correlates of erectile dysfunction in men on chronic hemodialysis: a multi-national cross-sectional study. Nephrology Dialysis Transplantation 2012;27(6):2479-2488. Impact factor 3.564. Citations: 2.

Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig J, Elder G, Strippoli GFM. Serum phosphorus, parathyroid hormone, and calcium levels and risks of death and cardiovascular disease in patients with cardiovascular disease. A systematic review and meta-analysis. Journal of the American Medical Association 2011;305(11):1119-27 [with editorial]. Impact factor: 30.0 Citations: 275.

Hamid AK, Richards AM, Crozier IG, Lainchbury JG, Melton I, Bridgman PG, Palmer SC, Frampton CM, Nicholls MG. Prediction of cardiac rhythm 1 year following cardioversion for atrial fibrillation. New Zealand Medical Journal 2011; 124 (1343):48-56. Impact factor: not available. Citations: 0.

Navaneethan SD, Palmer SC, Vecchio M, Craig J, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database of Systematic Reviews 2011 Feb 16;2:CD006023. Impact factor: 6.186. Citations: 4.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg A, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GFM. Systematic review: Erythropoiesis-stimulating agents in people with chronic kidney disease. Annals of Internal Medicine 2010; 153(1):22-33 [with editorial] Impact factor 16.7. Citations: 154.

Navaneethan SD, Palmer SC, Smith A, Johnson DW, Strippoli GFM. How to design a randomised trial. Nephrology 2010;15(8):732-9. Impact factor: 1.22. Citations: 3.

Smith A, Palmer SC, Johnson DW, Navaneethan SD, Strippoli GFM. How to conduct a randomised trial. Nephrology 2010;15(8):740-6. Impact factor: 1.22. Citations: 6.

Palmer SC, Strippoli GF. How to read critically a prognostic cohort study. Nephrology 2010;15(7):676-82. Impact factor: 1.22. Citations: 2.

Saglimbene VM, Maione A, Vecchio M, Nicolucci A, Pellegrini F, Navaneethan SD, Palmer S, Craig JC, Triolo G, Procaccini DA, Santoro A, Di Giulio S, Bonifati C, Di Micco L, La Rosa S, Murgo A, Di Toro Mammarella R, Sambati M, D’Ambrosio N, Greco V, Dagostino F, Giannoccaro G, Flammini A, Tedesco M, Boccia E, Di Franco D, Malaguti M, Falco M, Montalto G, Amaru S, Fici M, Amoroso L, D’Alonzo D, Valentini M, Palumbo R, Vischini G, Gori E, Vernaglione L, Casu D, Mandreoli M, Querques M, Hegbrant J, Johnson DW, Tognoni G, Strippoli GF, C E Dose TC. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials 2010;11(1):70. Impact factor: 2.02. Citations: 0.

Ellis KL, Pilbrow AP, Frampton CM, Doughty, RN, Whalley GA, Ellis CJ, Palmer BR, Skelton L, Yandle TG, Palmer SC, Troughton RW, Richards AM, Cameron VA. A common variant at chromosome 9P21.3 is associated with age of onset of coronary disease but not subsequent mortality. Circulation Cardiovascular Genetics 2010;3(3):286-93. Impact factor: 6.11. Citations: 29.

Palmer SC, Navaneethan S, Strippoli GFM. How to read a nephrology systematic review. Nephrology 2010;15(2):158-64. Impact factor: 1.22. Citations: 3.

Yandle TG, Mahagamasekera PMG, Ruygrok P, Palmer SC, Ansell G, Nicholls G, Pemberton CJ, Richards M. Cardiac tissue, coronary sinus and circulating forms of B-type natriuretic peptide in in patients with and without heart failure. Endocrine Journal 2010; 57(Suppl. 2), S325. Impact factor: 1.22. Citations: 1.

Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GFM. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD005633. DOI: 10.1002/14651858.CD005633.pub2. Impact factor: 6.186. Citations: 13.

Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GFM. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD008175. DOI: 10.1002/14651858.CD008175. Impact factor: 6.186. Citations: 65.

Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. American Journal of Kidney Diseases 2009; 54(4):619-37. Impact factor: 5.15. Citations: 112.

Chen Y-H, Yandle TG, Richards AM, Palmer SC. Urotensin II in human plasma: evidence for widespread tissue release. Clinical Chemistry 2009;55(11):2040-8. Impact factor: 3.03. Citations 11.

Palmer SC, Prickett TCR, Espiner EA, Yandle TG, Richards AM. Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function. Hypertension 2009; 54(3):612-8. Impact factor: 6.61. Citations: 48.

Palmer SC, Yandle TG, Nicholls MG, Frampton CM, Richards AM. Regional clearance of amino terminal pro-brain natriuretic peptide (NT-proBNP) from human plasma. European Journal of Heart Failure 2009;11(9):832. Impact factor: 3.71. Citations: 24.

Palmer SC, Yandle TG, Frampton CM, Troughton RW, Nicholls MG, Richards AM. Renal and cardiac function for long term (10-year) risk stratification after myocardial infarction. European Heart Journal 2009; 30(12):1486-94. Impact factor: 9.80. Citations: 12.

Palmer SC, Endre ZH, Richards AM, Yandle TG. Characterization of amino terminal pro-brain natriuretic peptide (NT-proBNP) in human urine. Clinical Chemistry 2009, 55;1126-1134. Impact factor: 3.169. Citations: 6.

Palmer SC, Nand K, Strippoli GF. Interventions for minimal change disease in adults with nephrotic syndrome. Cochrane Database of Systematic Reviews 2008, Issue 1. Art No.:CD001537. DOI: 10.1002/14651858.CD001537.pub4. Impact factor: 6.186. Citations: 12.

Palmer SC, McGregor DO, Macaskill P, Elder GE, Craig JC, Strippoli GFM. Vitamin D compounds for chronic kidney disease: A systematic review. Annals of Internal Medicine 2007; 147:840-853 [with editorial] Impact factor 16.7. Citations: 156.

Strippoli GF, Tong A, Palmer SC, Elder G, Craig JC. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Systematic Reviews 2006 Oct 18;(4):CD006254. Impact factor: 6.186. Citations: 34.

Strippoli GFM, Palmer SC, Tong A, Elder G, Craig JC. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. American Journal of Kidney Diseases 2006, 47(5):715-726. Impact factor: 5.15. Citations: 54.

Palmer SC, Strippoli GFM, McGregor DO. Interventions to prevent bone disease following renal transplantation. American Journal of Kidney Diseases 2005, 45:638-649. Impact factor: 5.15. Citations: 54.

Palmer SC, Strippoli GFM, McGregor DO. Interventions to prevent bone disease following renal transplantation. Cochrane Database of Systematic Reviews, Issue 2, 2005 Chichester, UK: John Wiley & Sons, Ltd. Impact factor: 6.186. Citations: 43.

Palmer S, Birks C, Dunbar J, Walker RJ. Simultaneous multiple tendon ruptures complicating a seizure in a haemodialysis patient. Nephrology 2004, 9:262-264. Impact factor: 1.22. Citations: 5